{"title":"[Initial empiric treatment of pneumonia and the new antibiotics].","authors":"M Parent","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":18049,"journal":{"name":"L'union medicale du Canada","volume":"123 1","pages":"14-8"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19100745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L P Boulet, P d'Amours, D Bérubé, M Rouleau, J G Parent, C Pelletier, C Touchette
Significant changes have occurred in aerosol therapy in the last few years. New devices have been developed to facilitate the administration of bronchodilator or anti-inflammatory drugs into the airways. Metered-dose inhaler with or without a spacer or powder devices are now considered the ideal mode of administration of aerosolized medications in the regular treatment of child or adult asthma as well as in COPD. In mild to moderate acute asthma, bronchodilators are ideally administered with a metered dose inhaler with a spacer device, nebulisation being required in only a minority of patients. Powder devices such as the Turbuhaler may also be useful in acute asthma but inspiratory flow should be sufficient, and their usefulness in this context remains to be better determined. In severe acute asthma or in patients unable to properly use the other inhalation devices, nebulisation can be used, with oxygen in the case of acute asthma. In patients requiring mechanical ventilation, administration of bronchodilators can be done with a metered-dose inhaler with a spacer device specifically designed for this purpose: it will replace nebulisation in most cases. In young children and infants unable to use spacer devices with a mouthpiece (< 5 years), wet nebulisation is still used during acute attacks of asthma. In these circumstances, the use of metered-dose inhalers with a spacer and mask are probably appropriate in some children but further studies are required to recommend their use.
{"title":"[Update on inhalation therapy in asthma and obstructive bronchopulmonary diseases].","authors":"L P Boulet, P d'Amours, D Bérubé, M Rouleau, J G Parent, C Pelletier, C Touchette","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Significant changes have occurred in aerosol therapy in the last few years. New devices have been developed to facilitate the administration of bronchodilator or anti-inflammatory drugs into the airways. Metered-dose inhaler with or without a spacer or powder devices are now considered the ideal mode of administration of aerosolized medications in the regular treatment of child or adult asthma as well as in COPD. In mild to moderate acute asthma, bronchodilators are ideally administered with a metered dose inhaler with a spacer device, nebulisation being required in only a minority of patients. Powder devices such as the Turbuhaler may also be useful in acute asthma but inspiratory flow should be sufficient, and their usefulness in this context remains to be better determined. In severe acute asthma or in patients unable to properly use the other inhalation devices, nebulisation can be used, with oxygen in the case of acute asthma. In patients requiring mechanical ventilation, administration of bronchodilators can be done with a metered-dose inhaler with a spacer device specifically designed for this purpose: it will replace nebulisation in most cases. In young children and infants unable to use spacer devices with a mouthpiece (< 5 years), wet nebulisation is still used during acute attacks of asthma. In these circumstances, the use of metered-dose inhalers with a spacer and mask are probably appropriate in some children but further studies are required to recommend their use.</p>","PeriodicalId":18049,"journal":{"name":"L'union medicale du Canada","volume":"123 1","pages":"23-31"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19100747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H Beauregard, M Somma, E Rasio, O Serri, N Aris-Jilwan, R Comtois, H Long, T Abribat, A Boucher, J Hardy
Acromegaly is a rare disease which can significantly reduce life expectancy. Clinical features are diverse and the patient may consult a variety of medical and surgical specialists before the diagnosis is suspected. However, the disease is easily confirmed by the appropriate laboratory tests, namely GH and IGF1 measurements. In most cases, acromegaly is secondary to a micro or macrosomatotrope pituitary adenoma. Those lesions are easily visualized by a pituitary CT Scan or Magnetic Resonance Imaging. Visual fields have to be evaluated by a neuro-ophthalmologist, and a thorough evaluation of other pituitary functions have to be performed. Selective removal of the adenoma by the transsphenoidal route is the treatment of choice for acromegaly. When performed by an experienced neurosurgeon, normalization of GH secretion can be expected in approximately 75% of cases. The surgical outcome is modulated by the volume, the extension of the tumor and the preoperative GH level. Octreotide, radiotherapy or bromocriptine are indicated whenever the patient remains with an elevated level of GH with persistency of symptoms.
{"title":"[The treatment of acromegaly].","authors":"H Beauregard, M Somma, E Rasio, O Serri, N Aris-Jilwan, R Comtois, H Long, T Abribat, A Boucher, J Hardy","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Acromegaly is a rare disease which can significantly reduce life expectancy. Clinical features are diverse and the patient may consult a variety of medical and surgical specialists before the diagnosis is suspected. However, the disease is easily confirmed by the appropriate laboratory tests, namely GH and IGF1 measurements. In most cases, acromegaly is secondary to a micro or macrosomatotrope pituitary adenoma. Those lesions are easily visualized by a pituitary CT Scan or Magnetic Resonance Imaging. Visual fields have to be evaluated by a neuro-ophthalmologist, and a thorough evaluation of other pituitary functions have to be performed. Selective removal of the adenoma by the transsphenoidal route is the treatment of choice for acromegaly. When performed by an experienced neurosurgeon, normalization of GH secretion can be expected in approximately 75% of cases. The surgical outcome is modulated by the volume, the extension of the tumor and the preoperative GH level. Octreotide, radiotherapy or bromocriptine are indicated whenever the patient remains with an elevated level of GH with persistency of symptoms.</p>","PeriodicalId":18049,"journal":{"name":"L'union medicale du Canada","volume":"122 6","pages":"489-95"},"PeriodicalIF":0.0,"publicationDate":"1993-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19291903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The department of psychiatry of the Université de Montréal has now organized a well structured research network in the area of child, adult and forensic psychiatry. The authors summarize the scientific approach according to research in these different sectors and believe that, although research in psychiatry now tends to promote diagnostic and treatment methods based more and more on neuro-sciences, it does not neglect the contribution of psychosocial and clinical aspects without which the human dimensions of mental illness and the objective of improvement of care to patients would be rapidly forgotten on behalf of disembodied research projects completely deprived of the relation with patients.
{"title":"[Research in psychiatry].","authors":"Y Lamontagne, A Lesage","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The department of psychiatry of the Université de Montréal has now organized a well structured research network in the area of child, adult and forensic psychiatry. The authors summarize the scientific approach according to research in these different sectors and believe that, although research in psychiatry now tends to promote diagnostic and treatment methods based more and more on neuro-sciences, it does not neglect the contribution of psychosocial and clinical aspects without which the human dimensions of mental illness and the objective of improvement of care to patients would be rapidly forgotten on behalf of disembodied research projects completely deprived of the relation with patients.</p>","PeriodicalId":18049,"journal":{"name":"L'union medicale du Canada","volume":"122 6","pages":"412, 416-8"},"PeriodicalIF":0.0,"publicationDate":"1993-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19291935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P Hamet, J Tremblay, Y L Sun, M Pravenec, J Kunes, V Kren
Thermosensitivity has been demonstrated in hypertensive rats and mice, and hypertension is frequent in hyperthermia-susceptible pigs. We have demonstrated that thermosensitivity segregates with hypertension in mice as a recessive trait in a single locus termed Tms. Since thermosensitivity can be demonstrated in cells obtained from neonatal hypertensive animals and persists after several passages in culture, it was of interest to study its cellular determinants. We undertook studies of candidate genes of cellular thermosensitivity, hsp70 being the major heat stress gene. First, we have observed an enhanced hsp70 mRNA accumulation in the hypertensive rat, mouse and human after heat shock of the whole animal, of its isolated organs or cultured cells. This increased accumulation of hsp70 mRNA in hypertension is due to its increased transcriptional rate. A restriction fragment length polymorphism (RFLP) of hsp70 was documented in hypertensive rats, which allowed the study of the segregation of this locus with hypertension in recombinant inbred strains of rats. At least one copy of hsp70 has been localized in RT1, the major histocompatibility complex of the rat, with polymorphism demonstrated with BamHI outside of the coding region of hsp70. This polymorphism segregates with 15 mmHg of systolic blood pressure. More recently, our studies led us to identify a polymorphism in another heat stress gene, hsp27. This polymorphism has been identified by PCR SSCP and is located in the 3' region, close to the termination translation codon.(ABSTRACT TRUNCATED AT 250 WORDS)
{"title":"[The stress gene in hypertension].","authors":"P Hamet, J Tremblay, Y L Sun, M Pravenec, J Kunes, V Kren","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Thermosensitivity has been demonstrated in hypertensive rats and mice, and hypertension is frequent in hyperthermia-susceptible pigs. We have demonstrated that thermosensitivity segregates with hypertension in mice as a recessive trait in a single locus termed Tms. Since thermosensitivity can be demonstrated in cells obtained from neonatal hypertensive animals and persists after several passages in culture, it was of interest to study its cellular determinants. We undertook studies of candidate genes of cellular thermosensitivity, hsp70 being the major heat stress gene. First, we have observed an enhanced hsp70 mRNA accumulation in the hypertensive rat, mouse and human after heat shock of the whole animal, of its isolated organs or cultured cells. This increased accumulation of hsp70 mRNA in hypertension is due to its increased transcriptional rate. A restriction fragment length polymorphism (RFLP) of hsp70 was documented in hypertensive rats, which allowed the study of the segregation of this locus with hypertension in recombinant inbred strains of rats. At least one copy of hsp70 has been localized in RT1, the major histocompatibility complex of the rat, with polymorphism demonstrated with BamHI outside of the coding region of hsp70. This polymorphism segregates with 15 mmHg of systolic blood pressure. More recently, our studies led us to identify a polymorphism in another heat stress gene, hsp27. This polymorphism has been identified by PCR SSCP and is located in the 3' region, close to the termination translation codon.(ABSTRACT TRUNCATED AT 250 WORDS)</p>","PeriodicalId":18049,"journal":{"name":"L'union medicale du Canada","volume":"122 6","pages":"470-7"},"PeriodicalIF":0.0,"publicationDate":"1993-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18904732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The mortality associated with coronary atherosclerosis has decreased by 30% to 40% in the last few decades. This reduction has followed major pharmacological and biotechnological advances and can possibly be attributed to better management of risk factors for coronary atherosclerosis and to more effective therapy of its late manifestations. Nevertheless, the coronary artery disease remains a major public health problem. It is responsible for 40% to 45% of deaths in our population and, although it becomes manifest later than previously, its incidence and prevalence may not have declined significantly. Recent studies suggest that progression of coronary atherosclerosis can be delayed, that regression can also occur, and that this can lead to a reduction in morbidity and mortality. Several types of interventions have been performed in these studies. Some of them such as a drastic modification in lifestyle, the administration of one or several hypocholesterolemic agents or partial ileal bypass have achieved these results by markedly lowering LDL or raising HDL cholesterol. Other manipulations of plasma lipoproteins are also possible, such as the administration of specific protein or enzyme inhibitors, anti-oxidants and omega-3 fatty acids. Calcium antagonists and possibly angiotensin converting-enzyme inhibitors slow the progression of early coronary lesions and prevent the appearance of new lesions. These interventions, in addition to influencing the size of the atherosclerotic plaque, can have other important effects. They can contribute to the preservation of integrity and function of endothelial cells.(ABSTRACT TRUNCATED AT 250 WORDS)
{"title":"[New treatment strategies in coronary disease].","authors":"M G Bourassa","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The mortality associated with coronary atherosclerosis has decreased by 30% to 40% in the last few decades. This reduction has followed major pharmacological and biotechnological advances and can possibly be attributed to better management of risk factors for coronary atherosclerosis and to more effective therapy of its late manifestations. Nevertheless, the coronary artery disease remains a major public health problem. It is responsible for 40% to 45% of deaths in our population and, although it becomes manifest later than previously, its incidence and prevalence may not have declined significantly. Recent studies suggest that progression of coronary atherosclerosis can be delayed, that regression can also occur, and that this can lead to a reduction in morbidity and mortality. Several types of interventions have been performed in these studies. Some of them such as a drastic modification in lifestyle, the administration of one or several hypocholesterolemic agents or partial ileal bypass have achieved these results by markedly lowering LDL or raising HDL cholesterol. Other manipulations of plasma lipoproteins are also possible, such as the administration of specific protein or enzyme inhibitors, anti-oxidants and omega-3 fatty acids. Calcium antagonists and possibly angiotensin converting-enzyme inhibitors slow the progression of early coronary lesions and prevent the appearance of new lesions. These interventions, in addition to influencing the size of the atherosclerotic plaque, can have other important effects. They can contribute to the preservation of integrity and function of endothelial cells.(ABSTRACT TRUNCATED AT 250 WORDS)</p>","PeriodicalId":18049,"journal":{"name":"L'union medicale du Canada","volume":"122 6","pages":"462-8"},"PeriodicalIF":0.0,"publicationDate":"1993-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19291895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kidney transplantation is a well recognized form of treatment for end-stage renal failure patients. Transplanted patients can hope for a prolonged and productive life. Many factors are responsible for the improvement of kidney transplantation over the last years. Despite its progress and success, many limitations still exist: shortage of kidney, humoral hypersensitivity or recipients, side effects of immunosuppressive medication and chronic rejection. Will the induction of specific tolerance to xenograft, with the help of transgenic biology, be the solution of tomorrow?
{"title":"[Renal transplantations: current reality and future challenges].","authors":"G St-Louis","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Kidney transplantation is a well recognized form of treatment for end-stage renal failure patients. Transplanted patients can hope for a prolonged and productive life. Many factors are responsible for the improvement of kidney transplantation over the last years. Despite its progress and success, many limitations still exist: shortage of kidney, humoral hypersensitivity or recipients, side effects of immunosuppressive medication and chronic rejection. Will the induction of specific tolerance to xenograft, with the help of transgenic biology, be the solution of tomorrow?</p>","PeriodicalId":18049,"journal":{"name":"L'union medicale du Canada","volume":"122 6","pages":"457-9"},"PeriodicalIF":0.0,"publicationDate":"1993-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19291897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}